English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Influenza is one of the infections registered on all continents. Despite the obvious scientific achievements pertaining to anti-epidemic measures, ARVI and influenza still present a major problem in medicine. Timely diagnosis of the causative agents for influenza and acute respiratory infections in humans allows for adjusting the treatment regimen and determining the correct vaccination tactics and choosing the appropriate vaccine variant during the interepidemic period. The arsenal of diagnostic methods still preserves serological techniques, which ensure the detection of specific antibodies in the blood in the disease dynamics and provide indirect evidence of the influenza virus circulation among humans. The purpose of this study was to carry out serological analysis of the circulation of influenza A and B viruses in the 2017–2018 epidemic season. The level of antibodies specific for the influenza virus hemagglutinins in blood serum was determined in the hemagglutination inhibition assay (HAI) and enzyme immunoassay (EIA). 60 serums collected from patients diagnosed with ARVI, influenza, ARD, and pneumonia in health care facilities located in the Almaty region during the 2017–2018 epidemic period were used for serological studies. EIA data showed that antibodies in 23.3% of cases (14 serums) were detected in high titers (1:80–1:320) against the A/H3N2 virus serosubtype, in 18.3% (11 samples) against influenza A/H1N1 viruses, and in 1.6% (1 sample) against the causative agent of influenza type B virus. Antibodies against influenza virus were detected by HAI assay in 31.6% of cases (19 samples), of which 16.6% (10 samples) were classified as A/H1N1 subtype and 13.3% (8 samples) as A/H3N2 subtype. Antibodies against influenza type B virus were found in 1.6% (1 sample). The results from serological studies of serums thereby indicate that in the 2017–2018 epidemic season the simultaneous circulation of influenza A (H1N1 and H3N2) and B viruses was observed in the Almaty region.

STUDY ON HERD IMMUNITY AGAINST INFLUENZA VIRUS AMONG THE POPULATION OF ALMATY REGION IN 2017–2018